A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 Mg/mL) for Intravenous Infusion

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

开始日期2023-12-18

申办/合作机构-

NCT06181760

/ Completed临床1期

A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult Volunteers

The goal of this clinical trial was to learn about a single dose of fenretinide in healthy volunteers, in both a fasted and fed state. The main questions to answer were:
* How well is a single dose of fenretinide tolerated? AND
* How is a single dose of fenretinide metabolized in healthy volunteers?
Participants will be asked to:
* Remain confined in a clinical research unit for 5 days after dosing.
* Provide blood samples for intense PK sampling and safety labs.
* Fast for 10 hours prior to administration of study drug (fasted cohorts).
* Consume a high fat meal prior to administration of study drug (fed cohort).
* Return to the clinic for a single follow-up visit for safety assessments.
The study will compare active fenretinide to placebo to see if fenretinide is more or less tolerable than placebo.

开始日期2023-11-22

申办/合作机构

Island Pharmaceuticals Ltd.

NCT05999435

/ Active, not recruiting临床2/3期

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADAPTIVE PHASE 2/3 STUDY OF THE EFFICACY OF LAU-7b IN THE TREATMENT OF ADULTS WITH LONG COVID AND MODERATE TO SEVERE SYMPTOMS

ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.

开始日期2023-11-20

申办/合作机构

Laurent Pharmaceuticals, Inc.

100 项与芬维A胺相关的临床结果

登录后查看更多信息

100 项与芬维A胺相关的转化医学

登录后查看更多信息

100 项与芬维A胺相关的专利（医药）

登录后查看更多信息

1,513

项与芬维A胺相关的文献（医药）

2025-03-01·Journal of Cosmetic Dermatology

A Functional Skincare Formulation Mixed With Retinyl Propionate, Hydroxypinacolone Retinoate, and Vitamin C on Antiaging and Whitening Han Women in Shanghai, China

Article

作者: Qiao, Jian ; Chen, Min ; Bian, Qianjin ; Zhang, Fan ; Fang, Wei

ABSTRACT:

Background:

Human skin is remodeled as a result of aging. Retinoids (or retinol derivatives) can intervene in this process, which can be optimally formulated and concentrated by providing maximum antiaging effects with minimal irritation.

Aims:

To determine the optimal ratio of two retinol derivatives hydroxypinacolone retinoate (HPR), retinol propionate (RP), and vitamin C (VitC) in dermal remodeling and preventing skin aging, and to investigate their synergistic antiaging and whitening effects in vitro and in vivo.

Methods:

An in vitro model of human skin fibroblast (HSF) was established to evaluate the cellular viability of VitC and/or RP/HPR treatment. We quantified the expression of genes associated with antiaging and retinol receptors in HSFs treated with VitC and/or RP/HPR. The research was conducted on 120 volunteer women to quantify the antiaging efficacy of functional skincare formulation.

Results:

A combination of VitC and RP/HPR at a weight ratio of 40:3 achieved the optimal and safe antiaging performance in vitro. Transcription of aging‐associated genes and the release of elastin and senescence‐associated secretory phenotypes (SASPs) increased significantly after UV irradiation, whereas VitC and RP/HPR cotreatment can inhibit this increase. The synergistic stimulation of VitC and RP/HPR cotreatment showed higher efficacy in the recovery ability of skin injury.

Conclusions:

Our results indicated the advanced skin antiaging and whitening effects of VitC and RP/HPR cotreatment in vitro and in vivo. A combination of VitC and RP/HPR is a potent strategy to postpone skin aging and improve skin whitening for middle‐aged women.

Trial Registration:

ClinicalTrials.gov identifier: 2020‐LS‐023

2025-01-01·Journal of Cystic Fibrosis

Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis

Article

作者: Zuckerman, Jonathan B ; Colin, Patrick ; Konstan, Michael W ; Kianicka, Irenej ; Middleton, Peter G ; Kotsimbos, Tom ; Radzioch, Danuta ; Polineni, Deepika ; Matouk, Elias ; Lands, Larry C ; Houle, Jean-Marie ; Liou, Theodore G ; Chmiel, James F ; Potvin, Diane ; Pislariu, Radu ; Bilodeau, Lara ; Nasr, Samya Z

BACKGROUND:

Lung inflammation is associated with tissue damage in cystic fibrosis (CF). LAU-7b, a novel oral drug candidate, was shown to control inflammation and stabilize CFTR protein in the epithelial membrane during inflammatory stress in preclinical models of CF.

METHODS:

A double-blind, randomized, placebo-controlled Phase 2 study was conducted to evaluate efficacy and safety of LAU-7b in adults with CF. LAU-7b or placebo was administered over 24 weeks as six 21-day treatment cycles each separated by 7 days. The primary efficacy endpoint was the absolute change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV₁) at 24 weeks.

RESULTS:

A total of 166 subjects received at least one dose of study drug (Intent-To-Treat population, ITT), of which 122 received ≥5 treatment cycles (Per-Protocol population, PP). Both treatment arms showed a mean lung function loss at 24 weeks of 1.18 ppFEV₁ points with LAU-7b and 1.95 ppFEV₁ with placebo, a 0.77 ppFEV₁ (40 s) difference, p=0.345, and a 0.95 ppFEV₁ (49 %) difference in the same direction in PP population, p=0.263. Primary analysis of mean ppFEV₁ through 24 weeks showed differences of 1.01 and 1.23 ppFEV₁, in the ITT (65 % less loss, p=0.067) and PP populations (78 % less loss, reaching statistical significance p=0.049), respectively. LAU-7b had an acceptable safety profile.

CONCLUSION:

Although the study did not meet its primary efficacy endpoint in the ITT population, LAU-7b was generally well tolerated and showed evidence of preservation of lung function to support further development.

2024-12-01·iScience

A transcriptome-based risk model in sepsis enables prognostic prediction and drug repositioning

Article

作者: Long, Qiuyue ; Mao, Jingsong ; Wu, Jing ; Ye, Hongli ; Zheng, Yali ; Li, Jiwei ; Song, Shixu ; Gao, Zhancheng ; Ke Li ; Li, Ran

Septic management presented a tremendous challenge due to heterogeneous host responses. We aimed to develop a risk model for early septic stratification based on transcriptomic signature. Here, we combined genes OLAH, LY96, HPGD, and ABLIM1 into a prognostic risk score model, which demonstrated exceptional performance in septic diagnosis (AUC = 0.99-1.00) and prognosis (AUC = 0.61-0.70), outperforming that of Mars and SRS endotypes. Also, the model unveiled immunosuppressive status in high-risk patients and a poor response to hydrocortisone in low-risk individuals. Single-cell transcriptome analysis further elucidated expression patterns and effects of the four genes across immune cell types, illustrating integrated host responses reflected by this model. Upon distinct transcriptional profiles of risk subgroups, we identified fenretinide and meloxicam as therapeutic agents, which significantly improved survival in septic mice models. Our study introduced a risk model that optimized risk stratification and drug repurposing of sepsis, thereby offering a comprehensive management approach.

项与芬维A胺相关的新闻（医药）

2025-01-13

·PRNewswire

SciTech Development Advances to Next Stage of Clinical Trial for ST-001 nanoFenretinide

**Encouraging Data from Accelerated Trial Supports Progress for T-cell Non-Hodgkin Lymphoma.** DETROIT, Jan. 13, 2025 /PRNewswire/ -- SciTech Development, a clinical-stage pharmaceutical company specializing in oncology, is pleased to announce the initiation of the next stage of its clinical trial for their lead drug candidate, ST-001 nanoFenretinide (ST-001) . This milestone follows the successful completion of the accelerated safety and dose-escalation stage, where ST-001 demonstrated exceptional safety, tolerability, and pharmacokinetic performance. Advancing the Phase 1a Trial with Clear Clinical Objectives The continuation of the ST-001 clinical trial aims to achieve several critical clinical objectives: Confirm that ST-001 achieves previously reported clinical response rates. Determine the pharmacological profile of intravenous fenretinide delivered using SciTech's novel nanoparticle delivery system, designed for drugs with poor water solubility. Determine the recommended treatment dose (RTD) to evaluate disease activity and response rates in the follow-on Phase 1b trial and the planned trial in Small Cell Lung Cancer. "The success of our accelerated Phase 1a trial marks a pivotal milestone, driving ST-001 into the next critical stage of development," said Earle Holsapple, CEO of SciTech Development. "We are thrilled about the potential of ST-001 nanoFenretinide and its promise to transform treatment outcomes for patients battling cancers such as T-cell Non-Hodgkin Lymphoma." About ST-001 nanoFenretinide ST-001 nanoFenretinide is a patented nanoparticle IV formulation that combines the drug fenretinide with biocompatible phospholipids. This groundbreaking new investigational drug overcomes bioavailability challenges, enhances therapeutic efficacy, and minimizes toxicity in cancer patients. Powered by SciTech's advanced delivery platform, ST-001 enables rapid delivery of effective doses of fenretinide to cancer cells, marking a breakthrough in hard-to-treat cancers. Encouraging Early Results in Phase 1a Accelerated Trial During the accelerated stage of the trial, ST-001 achieved significant milestones: Patient Enrollment is Complete for the accelerated stage of the clinical trial marking a significant accomplishment for patients with this rare disease. Therapeutic Responses Observed: Patients demonstrated partial responses and stable disease, marking an important step for trial advancement. Excellent Tolerability for ST-001 across all dose levels to date. Outstanding Pharmacokinetics: The nanoparticle delivery platform overcame longstanding bioavailability challenges, ensuring efficient delivery of fenretinide to tissues. Future Direction for ST-001 nanoFenretinide Building on the success of the accelerated Phase 1a stage, the trial begins detailed evaluation of clinical activity and response rates in T-cell lymphomas. The trial is actively underway at nine renowned medical centers across the country. Click here to learn more about the locations and patient trial criteria. Additionally, a separate trial targeting Small Cell Lung Cancer utilizing ST-001 is scheduled to begin in Q2 2025. About SciTech Development, Inc. SciTech Development, Inc., headquartered in Michigan, is an oncology focused, clinical-stage pharmaceutical company led by a world-class team. SciTech is committed to developing innovative, effective, and affordable cancer therapeutics that address unmet medical needs to bring hope to patients around the globe. To learn about SciTech and our latest advancements, please visit . Read the latest Press Release announcing "Promising Preliminary Results from the Phase 1a Accelerated Trial". Company Contact: David Schaffer Investor Relations [email protected] (727) 278-8118 SOURCE SciTech Development, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期

2024-12-19

·PRNewswire

A Success Story: Digital Opinion Leader Analysis for Cystic Fibrosis Treatments | DelveInsight

A case study on how a pharmaceutical company specializing in cystic fibrosis treatments turned to DelveInsight for comprehensive analysis and insights into the digital cystic fibrosis landscape in the UK. DelveInsight identified key Digital Opinion Leaders (DOLs) and synthesized their opinions, enabling the client to strategically leverage these insights for drug development, marketing, and patient advocacy, ensuring a competitive edge in the cystic fibrosis market. LAS VEGAS, Dec. 19, 2024 /PRNewswire/ -- DelveInsight, a leader in healthcare competitive intelligence and consulting company, published a success study on Digital Opinion Leader (DOL) Analysis in the Cystic Fibrosis Market . A pharmaceutical company specializing in cystic fibrosis treatments approached DelveInsight to conduct an in-depth analysis of DOLs in the UK. The client sought to identify key digital influencers and understand their perspectives on cystic fibrosis treatments, leveraging these insights to inform drug development, marketing strategies, and patient advocacy efforts. Cystic fibrosis is a life-limiting autosomal recessive genetic disorder that primarily affects the lungs and digestive system, caused by mutations in the CFTR gene. According to DelveInsight's latest Cystic Fibrosis Market and Epidem Forecast Report, the estimated total diagnosed prevalent cases of cystic fibrosis in the 7MM in 2023 were ~68K cases. The UK had the highest number of diagnosed cystic fibrosis cases, with nearly 11K, followed by France with 7.5K and Germany with 7K. In the EU4 and the UK, the cystic fibrosis market size was nearly USD 7 billion, accounting for almost 39.4% of the total 7MM market size in 2023. This is expected to increase significantly by 2034. Download the Sample Report to Explore Future Trends in the Cystic Fibrosis Market In the field of cystic fibrosis, DOLs play a significant role in shaping perceptions and influencing the direction of treatment, policy, and patient care. These are influential healthcare professionals or researchers who have an active online presence and contribute to discussions, research, and advocacy. For pharmaceutical companies developing cystic fibrosis treatments, understanding the DOL landscape is crucial for gaining insights into market dynamics and stakeholder perceptions and identifying strategic opportunities for drug development, marketing, and patient advocacy. Several medications have been approved to manage cystic fibrosis, with therapies targeting the CFTR protein to correct its defects. One of the most groundbreaking treatments is TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, which has revolutionized cystic fibrosis treatment by improving lung function in patients with specific genetic mutations. Other notable drugs include SYMDEKO (tezacaftor/ivacaftor) and ORKAMBI (lumacaftor/ivacaftor), which also target the CFTR protein. These therapies aim to address the root cause of the disease, improving symptoms and quality of life for patients. However, despite these advancements, the current treatment landscape still faces challenges, such as variability in treatment efficacy and accessibility to newer therapies for certain patient populations. The pipeline for cystic fibrosis treatments continues to evolve, with several promising drugs in the cystic fibrosis pipeline. Ensifentrine (Verona Pharmaceuticals) is a dual inhibitor of the enzymes responsible for inflammation and mucus production in the lungs, showing potential as an add-on therapy for patients with CF. VX-121/TEZ/VX-561 (Vertex Pharmaceuticals) is another exciting treatment, combining triple therapy to enhance CFTR function and improve lung function. LAU-7b (Laurent Pharmaceuticals Inc.) aims to restore CFTR function and reduce inflammation. Lonodelestat (Pari Pharma GmbH) is being investigated for its ability to reduce neutrophil elastase and inflammation in the lungs of CF patients. These drugs, if successful, could significantly improve treatment options and outcomes for CF patients. Several companies are at the forefront of developing treatments for cystic fibrosis. Eloxx Pharmaceuticals, Inc. focuses on treatments that aim to restore protein function in CF patients with specific genetic mutations. Vertex Pharmaceuticals is a leader in the CF market, with therapies like TRIKAFTA and ongoing pipeline developments. Santhera Pharmaceuticals is exploring potential treatments to address pulmonary issues in CF patients. DelveInsight helped the client by curating insights from the digital cystic fibrosis landscape and analyzing the opinions of key digital influencers. By identifying and analyzing these DOLs, DelveInsight provided actionable insights and strategic recommendations for the client. The company gained a deeper understanding of the market dynamics, stakeholder perceptions, and the evolving digital landscape surrounding cystic fibrosis. These insights were invaluable for informing drug development strategies, understanding the gaps, patient burden,, and patient advocacy initiatives. Armed with comprehensive information on DOLs and their impact, the client was better equipped to make informed decisions, enhance patient engagement, and improve the overall market approach for cystic fibrosis treatments. Our client approached us with multiple objectives: Understand the DOL Landscape in the UK for cystic fibrosis. Identify Key Digital Opinion Leaders influencing discussions about cystic fibrosis. Analyze the Opinions of DOLs on treatment options and emerging therapies. Leverage Insights to refine drug development, marketing strategies, and patient advocacy efforts. Outcome of DelveInsight's Digital Opinion Leader Analysis: We identified and profiled key digital opinion leaders (DOLs) in the UK cystic fibrosis community, focusing on those with strong online presence, high engagement, and CF expertise. Through content analysis, we gained insights into opinions, trends, and key areas like treatment, patient care, advocacy, and research within the CF community. We mapped the CF digital ecosystem, highlighting connections and interactions between DOLs and stakeholders revealing network dynamics and engagement patterns. We assessed the impact of DOLs using metrics like follower count, engagement rate, and content virality, helping clients prioritize engagement strategies and collaborations. DelveInsight specializes in comprehensive Key Opinion Leader (KOL) and Digital Opinion Leader (DOL) opinion analysis, offering deep insights into industry trends, expert perspectives, and influencer dynamics. Our expertise enables clients to identify and understand the nerve of the trends by providing analysis through the most impactful thought leaders and digital influencers. By leveraging our tailored strategies and data-driven approaches, we help businesses strengthen their approach, refine decision-making, and amplify their market impact. Connect with us today to explore how we can support your specific needs and discuss opportunities for strategic engagement. Request a Proposal Now ! Why Choose DelveInsight? DelveInsight offers comprehensive expertise in the respiratory disease domain, providing in-depth market research, consulting services, and pipeline analysis tailored to the evolving needs of the industry. With a sharp focus on respiratory conditions, DelveInsight delivers robust reports covering emerging therapies, market trends, competitive landscapes, and unmet needs. DelveInsight's respiratory-specific solutions empower stakeholders to make data-driven decisions, optimize their R&D efforts, and seize growth opportunities in the dynamic and rapidly advancing respiratory disease market. Market Assessment Services in the Genetic Disorders Segment, DelveInsight, provide a 360-degree view of the market landscape. Our expertise includes epidemiology-based market forecasts up to 2034, offering precise insights into current and future market share uptake of emerging therapies. These forecasts, combined with detailed analyses of emerging trends, competitive dynamics of the pipeline therapies, and unmet needs, enable stakeholders to strategize effectively and identify growth opportunities. Whether it's the pipeline analysis, pricing strategies, or competitive benchmarking, DelveInsight delivers actionable intelligence tailored to your goals. Contact us Today to discuss how our services can drive success in your endeavors within the genetic disorder market. Competitive Intelligence Services Tailored to Genetic Disorder Domain: DelveInsight's competitive intelligence services provide real-time, accurate insights across the different therapeutic domains and genetic disorders being one of our fortes, providing detailed insights into advancements across rare and inherited conditions such as cystic fibrosis, Duchenne muscular dystrophy, and sickle cell anemia etc to name a few. Our services analyze competitors' pipelines, clinical trial progress, gene and cell therapy innovations, and market entry strategies, as well as regulatory updates and patent landscapes specific to genetic disorders. This intelligence enables stakeholders to identify emerging threats, uncover growth opportunities, and develop targeted strategies to remain competitive in this evolving therapeutic area. Connect with us today to explore how we can help you succeed in the genetic disorders market. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform , PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2024-12-10

·PRNewswire

SCITECH DEVELOPMENT WELCOMES KEN MASSEY PH.D, AS STRATEGIC OPERATIONS ADVISOR

DETROIT, Dec. 10, 2024 /PRNewswire/ -- SciTech Development is thrilled to welcome Ken Massey, Ph.D., as Strategic Operations Advisor. With a wealth of experience in drug development, Dr. Massey has played a pivotal role in multiple programs leading to successful FDA New Drug Applications. His expertise further enhances SciTech's leadership team. Currently serving as Senior Director of Venture Development and Adjunct Professor of Pharmacology at Wayne State University (WSU), Dr. Massey has a distinguished career that spans academia, the pharmaceutical industry, and venture development. Prior to his tenure at WSU, Dr. Massey held key positions at Pfizer, where he was a scientist and director in the clinical cardiovascular group. During his time there, he oversaw the scientific and operational aspects of multiple drug development programs and accumulated experience across all phases of drug development, culminating in FDA approval. Dr. Massey's impressive career also includes his role as assistant professor at the University of Michigan Medical School, holding joint appointments in Anesthesiology and Pharmacology, as well as his time as managing director of LifeLine Ventures. "I am excited to join the talented SciTech Development team as the Strategic Operations Advisor. I look forward to contributing to the company's growth and success by driving operational excellence and supporting our strategic initiatives. I have been familiar with SciTech and its lead compound, ST-001, for many years and embrace this opportunity as it moves through clinical studies towards approval." said Massey. "More importantly, there is the potential to expand SciTech's oncology portfolio with additional indications, along with the long-term goal of offering safe and effective treatments for patients dealing with metastatic diseases." "With Dr. Massey's appointment, SciTech continues to strengthen its capabilities in strategic planning and operational execution as we move forward with our clinical studies and pipeline expansion," said Earle Holsapple, CEO of SciTech. "The company remains committed to developing innovative solutions that address the need to provide new therapeutics and better outcomes for patients facing difficult-to-treat cancers. We are grateful that Dr. Massey has joined our team. His comprehensive expertise will be invaluable to SciTech as the company advances its portfolio and prepares for future growth." About ST-001 nanoFenretinide (ST-001) ST-001, SciTech's lead drug candidate, is a patented nanoparticle formulation of fenretinide and biocompatible phospholipids, allowing for the rapid infusion (IV) of high-dose fenretinide. ST-001 solves bioavailability challenges, avoids triglyceride toxicity of prior formulations, and optimizes therapeutic efficacy. SciTech is currently in Phase 1 clinical trials for the treatment of T-Cell Non-Hodgkin Lymphoma and subtypes. ST-001 represents a novel therapeutic approach for targeting difficult-to-treat cancers, utilizing patented methods to improve drug safety and efficacy profiles while optimizing treatment outcomes. About SciTech Development SciTech Development, Inc. is a clinical-stage pharmaceutical company based in Michigan. With world-class leadership, SciTech is focused on bringing innovative, affordable, and effective cancer treatments to patients worldwide. For more information about SciTech Development, please visit . CONTACT: David Schaffer, Investor Relations [email protected] This press release may contain forward-looking statements that are subject to risks and uncertainties. These statements are based on current expectations and assumptions and are not guarantees of future performance. SOURCE SciTech Development, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期高管变更

100 项与芬维A胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04162	芬维A胺	-	DB05076

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床3期	加拿大	Laurent Pharmaceuticals, Inc.	2023-11-20
新型冠状病毒感染	临床3期	美国	Laurent Pharmaceuticals, Inc.	2020-06-29
BRCA突变阳性乳腺癌	临床3期	意大利	Istituto Europeo di Oncologia Srl	2009-12-01
HR阳性乳腺癌	临床3期	美国	National Cancer Institute	1995-10-01
乳腺癌	临床3期	-	Johnson & Johnson	-
乳腺癌	临床3期	-	Laurent Pharmaceuticals, Inc.	-
囊性纤维化	临床2期	美国	Laurent Pharmaceuticals, Inc.	2018-11-05
囊性纤维化	临床2期	澳大利亚	Laurent Pharmaceuticals, Inc.	2018-11-05
囊性纤维化	临床2期	加拿大	Laurent Pharmaceuticals, Inc.	2018-11-05
干性年龄相关性黄斑病变	临床2期	-	Sirion Therapeutics, Inc.	2006-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03265288 (APPLAUD, CTgov)	临床2期	囊性纤维化	166	LAU-7b (LAU-7b)	繭網鹽範壓構壓願鹹廠(憲壓淵觸衊鹽鑰鬱鬱壓) = 簾製襯獵鏇簾膚餘選鏇選艱積簾鏇鹹淵齋鬱選 (襯糧壓夢築夢簾齋糧遞, 簾醖築醖製鬱顧廠鹹觸 ~ 顧網構夢積糧簾繭選願) 更多	-	2024-10-09
				Placebo oral capsule (Placebo)	繭網鹽範壓構壓願鹹廠(憲壓淵觸衊鹽鑰鬱鬱壓) = 艱廠鹽遞餘鬱鏇選廠築選艱積簾鏇鹹淵齋鬱選 (襯糧壓夢築夢簾齋糧遞, 製願蓋憲顧積構憲網窪 ~ 簾糧餘積顧餘範獵願醖) 更多
NCT01553071 (Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies, Pubmed \| Cancer Chemother Pharmacol)	临床1期	晚期癌症	16	Fenretinide	壓築構築獵顧製範構襯(窪憲廠鬱顧鬱鹽簾選糧) = 糧廠壓觸醖範願鏇鏇膚蓋醖鹹鏇顧壓範蓋艱願 (壓範廠鹽顧襯網選製鹹 )	不佳	2023-08-01
NCT03265288 (APPLAUD, Biospace) 人工标引	临床2期	囊性纤维化	166	LAU-7b	積願糧鹹壓衊構網壓築(範製範鬱艱構鹹淵廠鏇): difference = 1.23, P-Value = 0.0486	积极	2022-11-03
				Placebo
NCT00546455 (CTgov)	临床2期	胰岛素抵抗 \| 肝炎 \| 肥胖 ... 更多	21	Fenretinide (A- Fenretinide)	鏇憲憲鹹衊艱顧觸餘艱(窪簾簾憲觸蓋鬱壓觸選) = 膚夢窪繭網淵蓋醖衊憲襯艱壓鏇餘鹽壓顧襯構 (糧願蓋範選選壓簾膚觸, 鹹鹹鹽鑰窪淵夢鹽範鹹 ~ 憲鹽窪鹹範衊選範壓窪) 更多	-	2021-02-10
				placebo (B-Placebo)	鏇憲憲鹹衊艱顧觸餘艱(窪簾簾憲觸蓋鬱壓觸選) = 餘齋窪網窪餘餘觸選窪襯艱壓鏇餘鹽壓顧襯構 (糧願蓋範選選壓簾膚觸, 範積獵鏇壓艱襯醖積網 ~ 夢鬱鏇壓遞積憲壓鏇艱) 更多
NCT00288067 (Pubmed \| Int J Radiat Oncol Biol Phys) 人工标引	临床1/2期	套细胞淋巴瘤 \| B细胞淋巴瘤	32	fenretinide	憲鹹襯齋繭窪餘鏇鏇鏇(鏇簾獵醖遞觸構鹹築繭) = No dose-limiting toxicities were observed. 艱觸願廠憲鏇遞鹹艱鬱 (壓廠餘簾壓窪醖願窪製 ) 更多	积极	2017-02-01
				fenretinide+rituximab
NCT00080899 (CTgov)	临床2期	复发性前列腺癌 \| 非转移性前列腺癌 \| 前列腺腺癌	23	Fenretinide (N-(4-hydroxyphenyl) retinamide [4-HPR])	壓簾夢淵簾積餘窪積膚 = 遞壓醖鑰顧遞觸鹹網糧齋積憲糧餘夢積鑰鹹憲 (顧膚窪蓋鹹壓選鏇鏇齋, 艱鏇網簾膚遞願範壓襯 ~ 範餘鹽餘壓獵範壓鏇構) 更多	-	2015-03-06
NCT00288067 (CTgov)	临床1/2期	复发性滤泡性淋巴瘤 \| 复发性边缘区淋巴瘤 \| 急性淋巴细胞白血病 ... 更多	32	Rituximab+Fenretinide (Fenretinide and Rituximab)	鹽製蓋網壓糧蓋壓獵廠 = 壓鹽廠選簾願艱願壓壓憲積艱艱構鬱構觸襯製 (繭顧簾蓋襯窪廠鑰衊遞, 繭淵壓鏇餘獵齋築鏇選 ~ 鏇鏇鬱鹽網膚廠遞獵願) 更多	-	2014-10-06
				Rituximab+Fenretinide (Fenretinide and Rituximab (Rituximab Naive))	願憲憲觸窪憲繭齋積艱 = 鏇夢觸鹽齋遞範觸窪鹽壓蓋鑰鏇範齋襯艱簾選 (願夢積觸醖糧繭糧醖鹹, 鬱壓淵憲築鹽夢鹽蓋醖 ~ 蓋糧鏇膚膚願顧觸鏇餘)
NCT00295919 (N2004-04, ASCO2014)	临床1期	神经母细胞瘤	80	4-HPR/LXS oral powder	鏇艱蓋遞鏇糧鬱廠壓積(齋製選鹽鏇餘襯簾範衊) = 獵鹹衊鹹積餘鹽壓醖遞齋顧憲構鹽鑰繭夢齋構 (醖築鬱窪夢獵艱蓋艱網, 1.35 ~ 36.9+) 更多	-	2014-05-20
				Ketoconazole	廠鹹簾鬱構獵齋鏇獵築(選製廠齋製窪積衊繭蓋) = 鹹製觸構鬱選網齋鹽窪鹹積製鑰膚衊鏇顧壓構 (構遞選襯顧憲遞蓋鑰顧, 14.6 ~ 22.1)
PhI-42 (ASCO2012)	临床1期	血液肿瘤	25	Fenretinide (4-HPR) intravenous emulsion	構夢夢鬱鬱廠顧鏇顧範(憲築膚廠鏇餘淵淵鹹鬱) = Reversible hypertriglyceridemia related to the intralipid vehicle accounted for 6/7 DLTs 鏇網齋憲餘鹹積鑰艱構 (築選鑰壓齋選膚齋齋糧 )	-	2012-05-20
AACR2012	临床1期	复发性神经母细胞瘤	-	4-HPR/LXS	遞構觸夢憲觸憲壓夢鏇(簾製積糧糧選積繭範壓) = 鏇醖廠膚獵襯獵構網鑰糧願窪膚壓選構餘鹽製 (壓網窪衊夢繭鏇獵廠艱 )	-	2012-04-15